---
title: "Spatial variation in azithromycin’s mortality benefit in the AVENIR trial, Dosso, Niger"
id: "medrxiv-3-estimation-of-fine-scale-spatial-heterogeneity-in-treatment-effects-in-a-large"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-3-estimation-of-fine-scale-spatial-heterogeneity-in-treatment-effects-in-a-large"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.11.03.26367216v1?rss=1"
published_at: "2026-11-05T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Spatial variation in azithromycin’s mortality benefit in the AVENIR trial, Dosso, Niger
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-3-estimation-of-fine-scale-spatial-heterogeneity-in-treatment-effects-in-a-large
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.11.03.26367216v1?rss=1)
- **Published At:** 2026-11-05T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This report is a secondary analysis of **AVENIR**, a cluster-randomized, placebo-controlled trial of biannual **azithromycin** given to children aged 1–59 months in Dosso, Niger (2020–2023). - Investigators used Poisson models to produce spatially continuous estimates of **child mortality** and the **average treatment effect** (ATE) across 1,390 villages. - The dataset included 276,452 person-years and 3,635 deaths; the overall mortality rate was 13.1 (per 1,000 person-years) and the ATE was −2.6 deaths per 1,000 person-years. - Mortality clustered highest in the south of the study area. - The treatment benefit was geographically concentrated in the southeast, forming a northwest–southeast gradient in effect sizes. - Aggregating village data to 160 primary health catchment areas retained broad mortality patterns but reduced detection of local heterogeneity. - Examining predicted unit-level treatment effects as a function of local mortality showed that underlying mortality explained much—but not all—of the observed heterogeneity in treatment benefit. - The analysis demonstrates a method to estimate localized treatment effects in large cluster-randomized trials and provides geographically resolved insights into where mass **azithromycin** distribution produced the largest survival gains. - The authors reported trial registration (NCT04224987) and ethical approvals; de-identified AVENIR trial data are available via the Open Science Framework, but village coordinates cannot be publicly shared to protect confidentiality.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=InlSi2vi9GqxFAUulFfcS__g2RuEQtl7jYcQUQAVxWA-1793900208.794392-1.2.1.1-Ame.xYiV.3JmOeFkjmtcy0NVS9dfwtzTmC7I2OAJAacWTHzUrXLL9_cXgustesT0) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.11.03.26367216v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Estimation of fine-scale spatial heterogeneity in treatment effects in a large cluster-randomized trial [ View ORCID Profile](http://orcid.org/0000-0002-3477-1757)Ariktha Srivathsan, [ View ORCID Profile](http://orcid.org/0009-0000-8464-3908)Mia A Navarro, Ahmed M. Arzika, Amza Abdou, Ramatou Maliki, Almou Ibrahim, Diallo Beidi, Nasser Galo, Nasser Harouna, Alio M Karamba, Moustapha Abarchi, Brittany Peterson, [ View ORCID Profile](http://orcid.org/0000-0002-3416-0817)Pearl Anne Ante-Testard, Elodie Lebas, Travis C Porco, [ View ORCID Profile](http://orcid.org/0000-0003-1504-9213)Marc Lipsitch, [ View ORCID Profile](http://orcid.org/0000-0002-1962-5321)Kieran S O'Brien, Thomas M. Lietman, [ View ORCID Profile](http://orcid.org/0000-0001-6105-7295)Benjamin F Arnold doi: https://doi.org/10.64898/2026.11.03.26367216 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Ariktha Srivathsan 1 Francis I Proctor Foundation, University of California San Francisco; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Ariktha%2BSrivathsan%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Srivathsan%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAriktha%2BSrivathsan%2B) * [ORCID record for Ariktha Srivathsan](http://orcid.org/0000-0002-3477-1757 "Open in new tab") * For correspondence: ariktha.srivathsan@ucsf.edu Mia A Navarro 2 Department of Epidemiology & Biostatistics, University of California San Francisco; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Mia%2BA%2BNavarro%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Navarro%20MA&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMia%2BA%2BNavarro%2B) * [ORCID record for Mia A Navarro](http://orcid.org/0009-0000-8464-3908 "Open in new tab") Ahmed M. Arzika 3 Centre de Recherche et Interventions en Santé Publique; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Ahmed%2B%2BM.%2BArzika%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Arzika%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAhmed%2B%2BM.%2BArzika%2B) Amza Abdou 4 Programe Nationale de Santé Oculaire; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Amza%2BAbdou%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Abdou%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAmza%2BAbdou%2B) Ramatou Maliki 3 Centre de Recherche et Interventions en Santé Publique; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Ramatou%2BMaliki%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Maliki%20R&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ARamatou%2BMaliki%2B) Almou Ibrahim 5 Programme National de Santé Oculaire; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Almou%2BIbrahim%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Ibrahim%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAlmou%2BIbrahim%2B) Diallo Beidi 6 Centre de Recherche et Interventions Santé Publique; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Diallo%2BBeidi%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Beidi%20D&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ADiallo%2BBeidi%2B) Nasser Galo 3 Centre de Recherche et Interventions en Santé Publique; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Nasser%2BGalo%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Galo%20N&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ANasser%2BGalo%2B) Nasser Harouna 3 Centre de Recherche et Interventions en Santé Publique; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Nasser%2BHarouna%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Harouna%20N&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ANasser%2BHarouna%2B) Alio M Karamba 3 Centre de Recherche et Interventions en Santé Publique; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Alio%2BM%2BKaramba%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Karamba%20AM&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAlio%2BM%2BKaramba%2B) Moustapha Abarchi 3 Centre de Recherche et Interventions en Santé Publique; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Moustapha%2BAbarchi%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Abarchi%20M&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMoustapha%2BAbarchi%2B) Brittany Peterson 1 Francis I Proctor Foundation, University of California San Francisco; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Brittany%2BPeterson%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Peterson%20B&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ABrittany%2BPeterson%2B) Pearl Anne Ante-Testard 1 Francis I Proctor Foundation, University of California San Francisco; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Pearl%2BAnne%2BAnte-Testard%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Ante-Testard%20PA&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3APearl%2BAnne%2BAnte-Testard%2B) * [ORCID record for Pearl Anne Ante-Testard](http://orcid.org/0000-0002-3416-0817 "Open in new tab") Elodie Lebas 1 Francis I Proctor Foundation, University of California San Francisco; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Elodie%2BLebas%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Lebas%20E&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AElodie%2BLebas%2B) Travis C Porco 1 Francis I Proctor Foundation, University of California San Francisco; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Travis%2BC%2BPorco%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Porco%20TC&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ATravis%2BC%2BPorco%2B) Marc Lipsitch 7 Stanford University * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Marc%2BLipsitch%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Lipsitch%20M&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMarc%2BLipsitch%2B) * [ORCID record for Marc Lipsitch](http://orcid.org/0000-0003-1504-9213 "Open in new tab") Kieran S O'Brien 1 Francis I Proctor Foundation, University of California San Francisco; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Kieran%2BS%2BO%27Brien%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=O%27Brien%20KS&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AKieran%2BS%2BO%2527Brien%2B) * [ORCID record for Kieran S O'Brien](http://orcid.org/0000-0002-1962-5321 "Open in new tab") Thomas M. Lietman 1 Francis I Proctor Foundation, University of California San Francisco; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Thomas%2B%2BM.%2BLietman%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Lietman%20T&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AThomas%2B%2BM.%2BLietman%2B) Benjamin F Arnold 1 Francis I Proctor Foundation, University of California San Francisco; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Benjamin%2BF%2BArnold%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Arnold%20BF&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ABenjamin%2BF%2BArnold%2B) * [ORCID record for Benjamin F Arnold](http://orcid.org/0000-0001-6105-7295 "Open in new tab") * [Abstract](https://www.medrxiv.org/content/10.64898/2026.11.03.26367216v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1339137/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.11.03.26367216v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1339137/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.11.03.26367216v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1339137/1) * [Supplementary material](https://www.medrxiv.org/content/10.64898/2026.11.03.26367216v1.supplementary-material)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_data/node:1339137/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.11.03.26367216v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1339137/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.11.03.26367216v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1339137/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Treatment effects in randomized trials may vary geographically, and estimating this variation is a broadly generalizable problem for large-scale, cluster-randomized trials. We conducted a secondary analysis of AVENIR, a cluster-randomized, placebo-controlled trial of biannual azithromycin distribution among children aged 1-59 months in Dosso, Niger (2020-2023). We assessed whether the survival benefit of mass azithromycin distribution varied geographically using Poisson models to estimate spatially continuous child mortality and average treatment effects (ATE). Among 1390 villages (276,452 person-years; 3635 deaths), the overall mortality rate was 13.1 and the ATE was -2.6 deaths per 1000 person-years. Mortality was highest in the south, whereas treatment benefit was concentrated in the southeast, following a northwest-southeast gradient. Aggregation of data to 160 primary health catchment areas preserved broad spatial patterns in mortality but attenuated local heterogeneity, suggesting that health catchment monitoring is sufficient for broad mortality surveillance. Examining unit-level, spatially predicted treatment effects as a function of mortality rate demonstrated that underlying mortality captured much, but not all, of the heterogeneity in treatment effects. The analysis demonstrates how to estimate localized treatment effects in large cluster-randomized trials and provides new insights into spatial heterogeneity in mortality and benefits of azithromycin distribution in Niger. ### Competing Interest Statement The authors have declared no competing interest. ### Clinical Trial NCT04224987 ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The trial received ethical approval from the Comité National Éthique pour la Recherche en Santé in Niger and the University of California, San Francisco Institutional Review Board. Community leaders gave verbal informed consent before study activities began, and verbal consent was also obtained from heads of household for census activities. Caregivers of eligible children gave verbal informed consent for treatment administration. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability De-identified AVENIR trial data is available through the Open Science Framework (https://osf.io/48q7k/). The village geographic coordinates data required for this analysis are not publicly sharable to protect participant confidentiality. ## Funder Information Declared Gates Foundation, https://ror.org/0456r8d26, OPP1210548, INV-002454 National Institute of Allergy and Infectious Diseases, R01AI175250, R01AI158884, R01AI166671 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.11.03.26367216v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.11.03.26367227v1 "Overall Outlook on Life and Cardiovascular Health Behaviors among Adolescent and Young Adult Females: A Cross-sectional Study")[Next ](https://www.medrxiv.org/content/10.64898/2026.11.01.26367023v1 "Application of Machine Learning and Deep Learning in diagnosis Covid19") Posted November 05, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.11.03.26367216v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/11/05/2026.11.03.26367216.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.11.03.26367216v1#p-5) [Supplementary Material ](https://www.medrxiv.org/content/10.64898/2026.11.03.26367216v1.supplementary-material) [ Data/Code](https://www.medrxiv.org/content/early/2026/11/05/2026.11.03.26367216.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Estimation of fine-scale spatial heterogeneity in treatment effects in a large cluster-randomized trial Ariktha Srivathsan, Mia A Navarro, Ahmed M. Arzika, Amza Abdou, Ramatou Maliki, Almou Ibrahim, Diallo Beidi, Nasser Galo, Nasser Harouna, Alio M Karamba, Moustapha Abarchi, Brittany Peterson, Pearl Anne Ante-Testard, Elodie Lebas, Travis C Porco, Marc Lipsitch, Kieran S O'Brien, Thomas M. Lietman, Benjamin F Arnold medRxiv 2026.11.03.26367216; doi: https://doi.org/10.64898/2026.11.03.26367216 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new
## Related Clinical Research

- [Eritrea validated by WHO for elimination of trachoma as a public health problem](https://medichelpline.com/clinical-feed/who-0-4-eritrea-eliminates-trachoma-a-major-public-health-milestone.md)
- [Intrapartum oral azithromycin vs placebo for maternal infection in South East Asia](https://medichelpline.com/clinical-feed/pubmed-43050477.md) (DOI: 10.1371/journal.pone.0346359)
- [Pharyngeal Gonorrhea vs Urogenital Strains in Ugandan Men: AMR and Genomic Differences](https://medichelpline.com/clinical-feed/pubmed-42415364.md) (DOI: 10.1093/infdis/jiag353)
- [Azithromycin MDA and antimicrobial resistance in Mali: LAKANA trial sub-study results](https://medichelpline.com/clinical-feed/plos-medicine-0-analysis-of-antimicrobial-resistance-in-the-lakana-trial-of-azithromycin.md)
- [Multidrug-resistant Salmonella in Fruit Bats and Shared Water Sources in Bangladesh](https://medichelpline.com/clinical-feed/plos-one-22-ecology-and-epidemiology-of-multidrug-resistance-salmonella-in-fruit-bats-and.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.